Uncategorized
Asgard Therapeutics appoints Dr Wolfram Brugger as CMO
Biotechnology company Asgard Therapeutics has appointed Dr Wolfram Brugger as Chief Medical Officer.
Brugger, who has been involved in more than 130 Phase I to III clinical oncology trials across a wide variety of cancer types, has been appointed to strengthen Asgard’s leadership as it prepares to transition to a clinical-stage biotech.
Brugger joins Asgard from Autolus Therapeutics, where he led the global clinical development programme of an autologous CD19 CAR–T therapy in haematological and autoimmune indications.
Prior to that, Brugger headed the global clinical development programme at MorphoSys and, at AstraZeneca, he was Global Medical Lead for Phase I/early Phase II trials for several oncology assets in numerous cancer types.
“I’ve always been driven by bringing new modalities to patients, and I am excited to be developing a ‘personalised off-the-shelf’ immunotherapy which has great potential to help patients with a wide variety of cancers,” Brugger said.
“Asgard’s in vivo cell reprogramming technology has transformative potential, and the pre-clinical proof-of-concept data, both published and upcoming data to be presented at key scientific conferences, is highly convincing.
“Having treated hundreds of cancer patients in clinical trials throughout my career, I look forward to utilising my experience to shape Asgard’s clinical strategy, driving AT-108 through clinical development.”
“Strengthening our leadership team with Wolfram, who is such a highly experienced clinical trials expert and practicing medical oncologist, is a privilege and we are excited to welcome him on board,” added Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics.
“Wolfram’s proven capabilities and track record will ensure that Asgard is perfectly positioned as we advance AT-108 towards the clinic.”
The post Asgard Therapeutics appoints Dr Wolfram Brugger as CMO appeared first on Drug Discovery World (DDW).
Uncategorized
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday.
The drug, a BTK inhibitor called fenebrutinib, demonstrated “the lowest relapse … Read More
Uncategorized
STAT+: With successful trials, Roche takes its MS drug to regulators, but safety questions loom
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive disability the disease causes.
Now the test is whether the drug, called fenebrutinib, can win the regulatory green light.
While three late-stage trials of the drug have shown it to be effective, analysts have homed in on some potentially worrying liver safety signals, an issue that previously prompted the Food and Drug Administration to reject an MS therapy developed by Sanofi. In data released Tuesday, researchers also disclosed that there were two drug-related deaths among patients who took fenebrutinib.
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive disability the disease causes.
Now the test is whether the drug, called fenebrutinib, can win the regulatory green light.
While three late-stage trials of the drug have shown it to be effective, analysts have homed in on some potentially worrying liver safety signals, an issue that previously prompted the Food and Drug Administration to reject an MS therapy developed by Sanofi. In data released Tuesday, researchers also disclosed that there were two drug-related deaths among patients who took fenebrutinib.
Uncategorized
STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs.
At the American Association of Cancer Research annual meeting here, the company is the talk of the town for the clinical trial success of daraxonrasib, their next generation targeted therapy, in advanced pancreatic cancer. And while the company presented more data on that drug on Tuesday, showing promising first line and combination data on daraxonrasib, scientists also showed in another session intriguing preclinical data on a completely new compound that may represent what comes after their current lineup.
That drug, currently called RM-055, is what RevMed’s CEO Mark Goldsmith is calling an entirely “novel class of catalytic inhibitors.” These are targeted therapies that not only block the RAS signaling that drives cancer, but molecularly turn the cancer protein off.
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs.
At the American Association of Cancer Research annual meeting here, the company is the talk of the town for the clinical trial success of daraxonrasib, their next generation targeted therapy, in advanced pancreatic cancer. And while the company presented more data on that drug on Tuesday, showing promising first line and combination data on daraxonrasib, scientists also showed in another session intriguing preclinical data on a completely new compound that may represent what comes after their current lineup.
That drug, currently called RM-055, is what RevMed’s CEO Mark Goldsmith is calling an entirely “novel class of catalytic inhibitors.” These are targeted therapies that not only block the RAS signaling that drives cancer, but molecularly turn the cancer protein off.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
STAT+: With successful trials, Roche takes its MS drug to regulators, but safety questions loom
STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
STAT+: Key GOP senators push back on Trump’s plan to cut NIH, reorganize HHS
Medicare indefinitely delays pilot plan to cover weight loss drugs
Alzheimer’s Linked to Cancer Mutations in Brain Immune Cells
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars